RAL+ATV/r in Comparison With TDF/FTC (or 3TC) +ATV/r in HIV Infected Patients (ARTE)

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified April 2013 by The Huesped Foundation
Sponsor:
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Pedro Cahn, The Huesped Foundation
ClinicalTrials.gov Identifier:
NCT01829802
First received: April 8, 2013
Last updated: NA
Last verified: April 2013
History: No changes posted
  Purpose

The purpose of this pilot study is to assess the efficacy and safety of the combination of RAL+ATV/r in comparison with TDF/FTC+ATV/r in HIV-1 infected patients presenting virologic failure and PI and TDF naïve.


Condition Intervention Phase
Chronic Infection With HIV
Drug: Ritonavir boosted Atazanavir
Drug: Raltegravir
Drug: TDF/FTC (or 3TC)
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Pilot Randomized, Open Label Study to Evaluate Efficacy and Safety of the Combination of RAL+ATV/r in Comparison With TDF/FTC+ATV/r in HIV Infected Patients, Who Failed an Initial NNRTI Containing Regimen

Resource links provided by NLM:


Further study details as provided by The Huesped Foundation:

Primary Outcome Measures:
  • Proportion of subjects with plasma HIV-1 RNA below the limit of detection (<50 copies/mL)in an intention to treat (exposed) analysis. [ Time Frame: 48 weeks ] [ Designated as safety issue: Yes ]
  • Proportion of subjects with SAEs and proportion with AEs leading to discontinuation. [ Time Frame: Through week 48 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Change from baseline on viral load [ Time Frame: 24 and 48 weeks ] [ Designated as safety issue: No ]
  • Change from baseline in lipid profile and renal function [ Time Frame: Through 48 weeks ] [ Designated as safety issue: Yes ]
  • Change from baseline in inflammation markers [ Time Frame: 24 and 48 weeks ] [ Designated as safety issue: No ]

Other Outcome Measures:
  • Number and type of resistance mutations in case of virologic failure [ Time Frame: Through 48 weeks ] [ Designated as safety issue: No ]

Estimated Enrollment: 50
Study Start Date: June 2013
Estimated Study Completion Date: May 2015
Estimated Primary Completion Date: February 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: RAL+ATA/r
Raltegravir 400 mg BID plus Ritonavir Boosted Atazanavir 300/100 mg QD
Drug: Ritonavir boosted Atazanavir
Ritonavir boosted Atazanavir 300/100 mg QD in combination with other drugs
Other Names:
  • Reyataz
  • Norvir
Drug: Raltegravir
Raltegravir 400 BID in combination with Ritonavir boosted Atazanavir 300/100 mg QD during 48 weeks
Other Name: Isentress
Active Comparator: TDF/FTC (or 3TC) +ATA/r
TDF/FTC (or 3TC)- Fixed dose combination of Tenofovir 300 mg plus Emtricitabine 200 mg (or Lamivudine 300 mg) QD plus Ritonavir Boosted Atazanavir 300/100 mg QD
Drug: Ritonavir boosted Atazanavir
Ritonavir boosted Atazanavir 300/100 mg QD in combination with other drugs
Other Names:
  • Reyataz
  • Norvir
Drug: TDF/FTC (or 3TC)
Fixed dose combination of Tenofovir 300 mg/Emtricitabine 200 mg or Tenofovir 300 mg/Lamivudine 300 mg plus Ritonavir Boosted Atazanavir 300/100mg given once a day
Other Names:
  • Truvada
  • TDF-FTC
  • TDF-3TC
  • Mivuten

Detailed Description:

Overall Study Design and Plan: Description

This is a pilot, randomized, open-label study. All the participants will be assigned to receive RAL+ATV/r or TDF/FTC+ATV/r. Patients will be evaluated at screening, randomization (day 0), and on weeks 4, 8, 12, 24, 36 and 48.

At the screening visit, subjects must be willing and able to give written (signed and dated) informed consent prior to any study specific procedures. They will receive a unique screening number and will undergo the study procedures associated with the screening visit. The investigator will evaluate whether the subject meets all eligibility criteria specified and record the details of the informed consent process and the results of this assessment in the subject's medical records. Two forms of the ICF will be signed, one for the subject and the other to file at the site.

At baseline visit, enrollment criteria will be reviewed and subjects who meet all of them will undergo study procedures. Subjects will receive instructions about study medications and dosing schedule. Subjects should start study medication within 24 hours of the baseline visit. Subjects will return to the investigator´s site for study visits and procedures. Subjects who prematurely discontinue the study must return for a discontinuation visit and undergo the study procedures identified for the discontinuation visit.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female subject ≥18 years of age.
  • Documented HIV-1 infection defined as a positive ELISA plus a confirmatory Western Blot; or a plasma HIV-1 RNA ≥10,000 copies/mL ever documented.
  • Patients who have failed their initial treatment containing NNRTI(s) + 2NRTI(s) combination therapy, according to virological criteria defined by two consecutive (at least 7 days apart) HIV-1 RNA results ≥500 copies/mL. Subject must be on stable HAART for at least the last 4 weeks.
  • No prior or current exposure to HIV-1 protease inhibitors and/or HIV-1 integrase inhibitors.
  • Subject must have susceptibility to ATV/r and TDF, as resulted by resistance testing at screening. RAL sensitivity is not required for patients never exposed to this drug in the country.
  • Subject has voluntarily signed ICF.
  • Subject can comply with protocol requirements.
  • Subject's general medical condition, in the investigator's opinion, does not interfere with assessments and completion of the trial.
  • Subject agrees not to take any medication during the study, including over the counter medicines or herbal preparations, without the approval of the trial physician.
  • If female, is not breastfeeding or pregnant.
  • If female, subject must be either postmenopausal for at least one year, surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy), or she must use 2 different methods of birth control including, at least, one barrier method, that are acceptable to both the subject and investigator, and willing to continue their use for at least 30 days after the end of the treatment period.
  • Subjects must have a life-expectancy of more than 1 year.

Exclusion Criteria:

  • Patient has a current (active) diagnosis of acute hepatitis due to any cause OR chronic hepatitis B and/or C WITH aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) >2.5 x upper limit of normal (ULN) AND/OR is likely to require hepatitis treatment in the next year.
  • Active hepatitis B infection (positive HBsAg), regardless of stage of infection.
  • Subject has a currently active AIDS defining illness (Category C conditions according to the CDC Classification System for HIV infection 1993) in the last 30 days.
  • Subjects with a laboratory abnormality Grade 3 or 4 with the following exceptions: pancreatic amylase, cholesterol, triglycerides, gamma glutamyl transpeptidase.
  • Screening laboratory analysis show any of the following abnormal results:

    • Hemoglobin <8.0 g/dL
    • Absolute neutrophil count <750 cells/µL
    • Platelet count <50,000 mm3
    • Creatinine >1.5 x ULN
  • Any condition that, in the investigators opinion, could compromise the subject's safety or adherence to the trial protocol.
  • The use of any study agent within 30 days prior to screening.
  • Use of immunosuppressive drugs, cytokines inhibitors or other cytokines in the previous year.
  • Any other condition (including, without limitation, the use of alcohol or drugs) that in the investigator's opinion may compromise the safety of the patient or his/her adherence to the protocol.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01829802

Contacts
Contact: Omar Sued, MD 54 11 4981 7777 omar.sued@huesoed.org.ar
Contact: Valeria Alvarez 54 11 4981 7777 ext 161 valeria.alvarez@huesped.org.ar

Locations
Argentina
Fundacion Huesped Not yet recruiting
Buenos Aires, Argentina, C1202ABB
Principal Investigator: Pedro Cahn, MD         
Sponsors and Collaborators
Pedro Cahn
Merck Sharp & Dohme Corp.
Investigators
Principal Investigator: Pedro Cahn, MD The Huesped Foundation
  More Information

No publications provided

Responsible Party: Pedro Cahn, President, The Huesped Foundation
ClinicalTrials.gov Identifier: NCT01829802     History of Changes
Other Study ID Numbers: FH-14, 50250
Study First Received: April 8, 2013
Last Updated: April 8, 2013
Health Authority: Argentina: Human Research Bioethics Committee

Keywords provided by The Huesped Foundation:
HIV
Raltegravir
Boosted atazanavir

Additional relevant MeSH terms:
HIV Infections
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Lamivudine
Ritonavir
Atazanavir
Reverse Transcriptase Inhibitors
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
Therapeutic Uses
Anti-HIV Agents
HIV Protease Inhibitors
Protease Inhibitors

ClinicalTrials.gov processed this record on August 27, 2014